G1 Therapeutics, Inc.
GTHXDrugs in Pipeline
6
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
Trilaciclib
TNBC - Triple-Negative Breast Cancer
Carboplatin
Small Cell Lung Cancer
G1T38
Carcinoma, Non-Small-Cell Lung
Cylophosphamide
Triple Negative Breast Cancer
Etoposide
Small Cell Lung Cancer
Topotecan
Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Trilaciclib | Phase 3 | TNBC - Triple-Negative Breast Cancer | - | - |
Carboplatin | Phase 3 | Small Cell Lung Cancer | - | - |
G1T38 | Phase 2 | Carcinoma, Non-Small-Cell Lung | - | - |
Cylophosphamide | Phase 2 | Triple Negative Breast Cancer | - | - |
Etoposide | Phase 2 | Small Cell Lung Cancer | - | - |
Topotecan | Phase 2 | Small Cell Lung Cancer | - | - |
Small Cell Lung Cancer
3 drugs in this indication
Carcinoma, Non-Small-Cell Lung
1 drug in this indication
Triple Negative Breast Cancer
1 drug in this indication
TNBC - Triple-Negative Breast Cancer
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Frequently asked questions
What is in G1 Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 6 drug candidates in G1 Therapeutics, Inc.'s (GTHX) pipeline across Phase 3, Phase 2. Its lead program is Trilaciclib (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is G1 Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for G1 Therapeutics, Inc. (GTHX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track GTHX biotech catalysts?→
Add GTHX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow G1 Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.